<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38693436</PMID><DateCompleted><Year>2024</Year><Month>05</Month><Day>01</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>06</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1591-9528</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>May</Month><Day>02</Day></PubDate></JournalIssue><Title>Clinical and experimental medicine</Title><ISOAbbreviation>Clin Exp Med</ISOAbbreviation></Journal><ArticleTitle>Inclusion body myositis, viral infections, and TDP-43: a narrative review.</ArticleTitle><Pagination><StartPage>91</StartPage><MedlinePgn>91</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">91</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10238-024-01353-9</ELocationID><Abstract><AbstractText>The ubiquitous RNA-processing molecule TDP-43 is involved in neuromuscular diseases such as inclusion body myositis, a late-onset acquired inflammatory myopathy. TDP-43 solubility and function are disrupted in certain viral infections. Certain viruses, high viremia, co-infections, reactivation of latent viruses, and post-acute expansion of cytotoxic T cells may all contribute to inclusion body myositis, mainly in an age-shaped immune landscape. The virally induced senescent, interferon gamma-producing cytotoxic CD8+&#x2009;T cells with increased inflammatory, and cytotoxic features are involved in the occurrence of inclusion body myositis in most such cases, in a genetically predisposed host. We discuss the putative mechanisms linking inclusion body myositis, TDP-43, and viral infections untangling the links between viruses, interferon, and neuromuscular degeneration could shed a light on the pathogenesis of the inclusion body myositis and other TDP-43-related neuromuscular diseases, with possible therapeutic implications.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>V&#x103;c&#x103;ra&#x15f;</LastName><ForeName>Vitalie</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, "Iuliu Ha&#x163;ieganu" University of Medicine and Pharmacy, Cluj-Napoca, 43, Victor Babe&#x15f; St, 400012, Cluj-Napoca, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology Department of Cluj, County Emergency Hospital, 3-5, Clinicilor St, 400347, Cluj-Napoca, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Vulturar</LastName><ForeName>Romana</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-2476-9706</Identifier><AffiliationInfo><Affiliation>Department of Molecular Sciences, "Iuliu Ha&#x163;ieganu" University of Medicine and Pharmacy Cluj-Napoca, 6, Pasteur St, 400349, Cluj-Napoca, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cognitive Neuroscience Laboratory, University Babe&#x15f;-Bolyai, 30, F&#xe2;nt&#xe2;nele St, 400294, Cluj-Napoca, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Association for Innovation in Rare Inflammatory, Metabolic, Genetic Diseases INNOROG, 30E, F&#x103;getului St, 400497, Cluj-Napoca, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chi&#x15f;</LastName><ForeName>Adina</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-1651-0860</Identifier><AffiliationInfo><Affiliation>Department of Molecular Sciences, "Iuliu Ha&#x163;ieganu" University of Medicine and Pharmacy Cluj-Napoca, 6, Pasteur St, 400349, Cluj-Napoca, Romania. adinachis82@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cognitive Neuroscience Laboratory, University Babe&#x15f;-Bolyai, 30, F&#xe2;nt&#xe2;nele St, 400294, Cluj-Napoca, Romania. adinachis82@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Association for Innovation in Rare Inflammatory, Metabolic, Genetic Diseases INNOROG, 30E, F&#x103;getului St, 400497, Cluj-Napoca, Romania. adinachis82@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Damian</LastName><ForeName>Laura</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-5735-3929</Identifier><AffiliationInfo><Affiliation>Association for Innovation in Rare Inflammatory, Metabolic, Genetic Diseases INNOROG, 30E, F&#x103;getului St, 400497, Cluj-Napoca, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Rheumatology, Centre for Rare Autoimmune and Autoinflammatory Diseases, Emergency, Clinical County Hospital Cluj, 2-4, Clinicilor St, 400006, Cluj-Napoca, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CMI Reumatologie Dr. Damian, 6-8, Petru Maior St, 400002, Cluj-Napoca, Romania.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>05</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Clin Exp Med</MedlineTA><NlmUniqueID>100973405</NlmUniqueID><ISSNLinking>1591-8890</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000598624">TARDBP protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D018979" MajorTopicYN="Y">Myositis, Inclusion Body</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014777" MajorTopicYN="Y">Virus Diseases</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="Y">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Inclusion body myositis</Keyword><Keyword MajorTopicYN="N">Interferon gamma</Keyword><Keyword MajorTopicYN="N">Long&#xa0;COVID</Keyword><Keyword MajorTopicYN="N">Myositis triggers</Keyword><Keyword MajorTopicYN="N">TDP-43</Keyword></KeywordList><CoiStatement>The authors declare that they have no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>4</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>5</Month><Day>2</Day><Hour>0</Hour><Minute>49</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>5</Month><Day>2</Day><Hour>0</Hour><Minute>48</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>5</Month><Day>1</Day><Hour>23</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>5</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38693436</ArticleId><ArticleId IdType="pmc">PMC11062973</ArticleId><ArticleId IdType="doi">10.1007/s10238-024-01353-9</ArticleId><ArticleId IdType="pii">10.1007/s10238-024-01353-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Greenberg SA. Inclusion body myositis: clinical features and pathogenesis. Nat Rev Rheumatol. 2019;15(5):257&#x2013;272. doi: 10.1038/s41584-019-0186-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41584-019-0186-x</ArticleId><ArticleId IdType="pubmed">30837708</ArticleId></ArticleIdList></Reference><Reference><Citation>McLeish E, Slater N, Sooda A, Wilson A, Coudert JD, Lloyd TE, Needham M. Inclusion body myositis: the interplay between ageing, muscle degeneration and autoimmunity. Best Pract Res Clin Rheumatol. 2022;36(2):101761. doi: 10.1016/j.berh.2022.101761.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.berh.2022.101761</ArticleId><ArticleId IdType="pubmed">35760741</ArticleId></ArticleIdList></Reference><Reference><Citation>Lundberg IE, de Visser M, Werth VP. Classification of myositis. Nat Rev Rheumatol. 2018;14(5):269&#x2013;278. doi: 10.1038/nrrheum.2018.41.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrrheum.2018.41</ArticleId><ArticleId IdType="pubmed">29651121</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelke C, Kleefeld F, Preusse C, Ruck T, Stenzel W. Inclusion body myositis and associated diseases: an argument for shared immune pathologies. Acta Neuropathol Commun. 2022;10(1):84. doi: 10.1186/s40478-022-01389-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-022-01389-6</ArticleId><ArticleId IdType="pmc">PMC9164382</ArticleId><ArticleId IdType="pubmed">35659120</ArticleId></ArticleIdList></Reference><Reference><Citation>Snedden AM, Kellett KAB, Lilleker JB, Hooper NM, Chinoy H. The role of protein aggregation in the pathogenesis of inclusion body myositis. Clin Exp Rheumatol. 2022;40(2):414&#x2013;424. doi: 10.55563/clinexprheumatol/pp0oso.</Citation><ArticleIdList><ArticleId IdType="doi">10.55563/clinexprheumatol/pp0oso</ArticleId><ArticleId IdType="pubmed">35225225</ArticleId></ArticleIdList></Reference><Reference><Citation>Versluys L, Ervilha Pereira P, Schuermans N, De Paepe B, De Bleecker JL, Bogaert E, Dermaut B. Expanding the TDP-43 proteinopathy pathway from neurons to muscle: physiological and pathophysiological functions. Front Neurosci. 2022;16:815765. doi: 10.3389/fnins.2022.815765.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2022.815765</ArticleId><ArticleId IdType="pmc">PMC8851062</ArticleId><ArticleId IdType="pubmed">35185458</ArticleId></ArticleIdList></Reference><Reference><Citation>Weihl CC, Temiz P, Miller SE, Watts G, Smith C, Forman M, Hanson PI, et al. TDP-43 accumulation in inclusion body myopathy muscle suggests a common pathogenic mechanism with frontotemporal dementia. J Neurol Neurosurg Psychiatry. 2008;79(10):1186&#x2013;1189. doi: 10.1136/jnnp.2007.131334.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2007.131334</ArticleId><ArticleId IdType="pmc">PMC2586594</ArticleId><ArticleId IdType="pubmed">18796596</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x160;u&#x161;njar U, &#x160;krabar N, Brown AL, Abbassi Y, Phatnani H, NYGC ALS Consortium, Cortese A, et al. Cell environment shapes TDP-43 function with implications in neuronal and muscle disease. Commun Biol. 2022;5(1):314. 10.1038/s42003-022-03253-8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8983780</ArticleId><ArticleId IdType="pubmed">35383280</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E. TDP-43 post-translational modifications in health and disease. Expert Opin Ther Targets. 2018;22(3):279&#x2013;293. doi: 10.1080/14728222.2018.1439923.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14728222.2018.1439923</ArticleId><ArticleId IdType="pubmed">29431050</ArticleId></ArticleIdList></Reference><Reference><Citation>Britson KA, Ling JP, Braunstein KE, Montagne JM, Kastenschmidt JM, Wilson A, Ikenaga C, et al. Loss of TDP-43 function and rimmed vacuoles persist after T cell depletion in a xenograft model of sporadic inclusion body myositis. Sci Transl Med. 2022;14(628):eabi9196. doi: 10.1126/scitranslmed.abi9196.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abi9196</ArticleId><ArticleId IdType="pmc">PMC9118725</ArticleId><ArticleId IdType="pubmed">35044790</ArticleId></ArticleIdList></Reference><Reference><Citation>Salajegheh M, Pinkus JL, Taylor JP, Amato AA, Nazareno R, Baloh RH, Greenberg SA. Sarcoplasmic redistribution of nuclear TDP-43 in inclusion body myositis. Muscle Nerve. 2009;40(1):19&#x2013;31. doi: 10.1002/mus.21386.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.21386</ArticleId><ArticleId IdType="pmc">PMC2700211</ArticleId><ArticleId IdType="pubmed">19533646</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahic Z, Buratti E, Cappelli S. Reviewing the potential links between viral infections and TDP-43 proteinopathies. Int J Mol Sci. 2023;24(2):1581. doi: 10.3390/ijms24021581.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms24021581</ArticleId><ArticleId IdType="pmc">PMC9867397</ArticleId><ArticleId IdType="pubmed">36675095</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunker W, Ye X, Zhao Y, Liu L, Richardson A, Karijolich J. TDP-43 prevents endogenous RNAs from triggering a lethal RIG-I-dependent interferon response. Cell Rep. 2021;35(2):108976. doi: 10.1016/j.celrep.2021.108976.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2021.108976</ArticleId><ArticleId IdType="pmc">PMC8109599</ArticleId><ArticleId IdType="pubmed">33852834</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu W, Wang Z, Liu L, Yang Z, Liu S, Ma Z, Liu Y, et al. LncRNA Malat1 inhibition of TDP43 cleavage suppresses IRF3-initiated antiviral innate immunity. Proc Natl Acad Sci U S A. 2020;117(38):23695&#x2013;23706. doi: 10.1073/pnas.2003932117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2003932117</ArticleId><ArticleId IdType="pmc">PMC7519350</ArticleId><ArticleId IdType="pubmed">32907941</ArticleId></ArticleIdList></Reference><Reference><Citation>Yl&#xe4;-Anttila P. Autophagy receptors as viral targets. Cell Mol Biol Lett. 2021;26(1):29. doi: 10.1186/s11658-021-00272-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s11658-021-00272-x</ArticleId><ArticleId IdType="pmc">PMC8222950</ArticleId><ArticleId IdType="pubmed">34167456</ArticleId></ArticleIdList></Reference><Reference><Citation>Askanas V, Engel WK. Inclusion-body myositis: newest concepts of pathogenesis and relation to aging and Alzheimer disease. J Neuropathol Exp Neurol. 2001;60(1):1&#x2013;14. doi: 10.1093/jnen/60.1.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnen/60.1.1</ArticleId><ArticleId IdType="pubmed">11202170</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubowsky M, Theunissen F, Carr JM, Rogers ML. The molecular link between TDP-43, endogenous retroviruses and inflammatory neurodegeneration in amyotrophic lateral sclerosis: a potential target for Triumeq, an antiretroviral therapy. Mol Neurobiol. 2023;60(11):6330&#x2013;6345. doi: 10.1007/s12035-023-03472-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-023-03472-y</ArticleId><ArticleId IdType="pmc">PMC10533598</ArticleId><ArticleId IdType="pubmed">37450244</ArticleId></ArticleIdList></Reference><Reference><Citation>Morosetti R, Broccolini A, Sancricca C, Gliubizzi C, Gidaro T, Tonali PA, Ricci E, Mirabella M. Increased aging in primary muscle cultures of sporadic inclusion-body myositis. Neurobiol Aging. 2010;31(7):1205&#x2013;1214. doi: 10.1016/j.neurobiolaging.2008.08.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2008.08.011</ArticleId><ArticleId IdType="pubmed">18823681</ArticleId></ArticleIdList></Reference><Reference><Citation>Germain MA, Chatel-Chaix L, Gagn&#xe9; B, Bonneil &#xc9;, Thibault P, Pradezynski F, de Chassey B, et al. Elucidating novel hepatitis C virus-host interactions using combined mass spectrometry and functional genomics approaches. Mol Cell Proteomics. 2014;13(1):184&#x2013;203. doi: 10.1074/mcp.M113.030155.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/mcp.M113.030155</ArticleId><ArticleId IdType="pmc">PMC3879614</ArticleId><ArticleId IdType="pubmed">24169621</ArticleId></ArticleIdList></Reference><Reference><Citation>Lloyd TE, Pinal-Fernandez I, Michelle EH, Christopher-Stine L, Pak K, Sacktor N, Mammen AL. Overlapping features of polymyositis and inclusion body myositis in HIV-infected patients. Neurology. 2017;88(15):1454&#x2013;1460. doi: 10.1212/WNL.0000000000003821.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000003821</ArticleId><ArticleId IdType="pmc">PMC5386438</ArticleId><ArticleId IdType="pubmed">28283597</ArticleId></ArticleIdList></Reference><Reference><Citation>Saldi TK, Ash PE, Wilson G, Gonzales P, Garrido-Lecca A, Roberts CM, Dostal V, et al. TDP-1, the Caenorhabditis elegans ortholog of TDP-43, limits the accumulation of double-stranded RNA. EMBO J. 2014;33(24):2947&#x2013;2966. doi: 10.15252/embj.201488740.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.201488740</ArticleId><ArticleId IdType="pmc">PMC4282642</ArticleId><ArticleId IdType="pubmed">25391662</ArticleId></ArticleIdList></Reference><Reference><Citation>Fung G, Shi J, Deng H, Hou J, Wang C, Hong A, Zhang J, et al. Cytoplasmic translocation, aggregation, and cleavage of TDP-43 by enteroviral proteases modulate viral pathogenesis. Cell Death Differ. 2015;22(12):2087&#x2013;2097. doi: 10.1038/cdd.2015.58.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cdd.2015.58</ArticleId><ArticleId IdType="pmc">PMC4816113</ArticleId><ArticleId IdType="pubmed">25976304</ArticleId></ArticleIdList></Reference><Reference><Citation>Rathore A, Iketani S, Wang P, Jia M, Sahi V, Ho DD. CRISPR-based gene knockout screens reveal deubiquitinases involved in HIV-1 latency in two Jurkat cell models. Sci Rep. 2020;10(1):5350. doi: 10.1038/s41598-020-62375-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-62375-3</ArticleId><ArticleId IdType="pmc">PMC7093534</ArticleId><ArticleId IdType="pubmed">32210344</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Lu S, Gu J, Xia W, Zhang S, Zhang S, Wang Y, et al. SARS-CoV-2 impairs the disassembly of stress granules and promotes ALS-associated amyloid aggregation. Protein Cell. 2022;13(8):602&#x2013;614. doi: 10.1007/s13238-022-00905-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13238-022-00905-7</ArticleId><ArticleId IdType="pmc">PMC8983322</ArticleId><ArticleId IdType="pubmed">35384603</ArticleId></ArticleIdList></Reference><Reference><Citation>Xue Y, Zhang J, Ke J, Zeng L, Cheng K, Han X, Chen F, et al. LncGBP9 knockdown alleviates myocardial inflammation and apoptosis in mice with acute viral myocarditis via suppressing NF-kappaB signaling pathamianway. Inflamm Res. 2022;71(12):1559&#x2013;1576. doi: 10.1007/s00011-022-01644-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00011-022-01644-5</ArticleId><ArticleId IdType="pubmed">36301340</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang YH, Dubnau J. Endogenous retroviruses and TDP-43 proteinopathy form a sustaining feedback driving intercellular spread of Drosophila neurodegeneration. Nat Commun. 2023;14(1):966. doi: 10.1038/s41467-023-36649-.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-36649-</ArticleId><ArticleId IdType="pmc">PMC9944888</ArticleId><ArticleId IdType="pubmed">36810738</ArticleId></ArticleIdList></Reference><Reference><Citation>Keller CW, Schmidt J, Lunemann JD. Immune and myodegenerative pathomechanisms in inclusion body myositis. Ann Clin Transl Neurol. 2017;4(6):422&#x2013;445. doi: 10.1002/acn3.419.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.419</ArticleId><ArticleId IdType="pmc">PMC5454400</ArticleId><ArticleId IdType="pubmed">28589170</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishino H, Engel AG, Rima BK. Inclusion body myositis: the mumps virus hypothesis. Ann Neurol. 1989;25(3):260&#x2013;264. doi: 10.1002/ana.410250309.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410250309</ArticleId><ArticleId IdType="pubmed">2729916</ArticleId></ArticleIdList></Reference><Reference><Citation>Agergaard J, Leth S, Pedersen TH, Harbo T, Blicher JU, Karlsson P, Ostergaard L, et al. Myopathic changes in patients with long-term fatigue after COVID-19. Clin Neurophysiol. 2021;132(8):1974&#x2013;1981. doi: 10.1016/j.clinph.2021.04.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2021.04.009</ArticleId><ArticleId IdType="pmc">PMC8102077</ArticleId><ArticleId IdType="pubmed">34020890</ArticleId></ArticleIdList></Reference><Reference><Citation>Galeotti C, Bayry J. Autoimmune and inflammatory diseases following COVID-19. Nat Rev Rheumatol. 2020;16(8):413&#x2013;414. doi: 10.1038/s41584-020-0448-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41584-020-0448-7</ArticleId><ArticleId IdType="pmc">PMC7271827</ArticleId><ArticleId IdType="pubmed">32499548</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen TM, Kabotyanski EB, Reineke LC, Shao J, Xiong F, Lee JH, Dubrulle J, et al. The SINEB1 element in the long non-coding RNA Malat1 is necessary for TDP-43 proteostasis. Nucleic Acids Res. 2020;8(5):2621&#x2013;2642. doi: 10.1093/nar/gkz1176.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkz1176</ArticleId><ArticleId IdType="pmc">PMC7049706</ArticleId><ArticleId IdType="pubmed">31863590</ArticleId></ArticleIdList></Reference><Reference><Citation>Li XL, Ezelle HJ, Hsi TY, Hassel BA. A central role for RNA in the induction and biological activities of type 1 interferons. Wiley Interdiscip Rev RNA. 2011;2(1):58&#x2013;78. doi: 10.1002/wrna.32.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/wrna.32</ArticleId><ArticleId IdType="pubmed">21956969</ArticleId></ArticleIdList></Reference><Reference><Citation>Piazzi M, Bavelloni A, Cenni V, Faenza I, Blalock WL. Revisiting the role of GSK3, a modulator of innate immunity, in idiopathic inclusion body myositis. Cells. 2021;10(11):3255. doi: 10.3390/cells10113255.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10113255</ArticleId><ArticleId IdType="pmc">PMC8625526</ArticleId><ArticleId IdType="pubmed">34831477</ArticleId></ArticleIdList></Reference><Reference><Citation>Sreedharan J, Neukomm LJ, Brown Jr RH, Freeman MR. Age-dependent TDP-43-mediated motor neuron degeneration requires GSK3, hat-trick, and xmas-2. Curr Biol. 2015;25(16):2130&#x2013;2136. doi: 10.1016/j.cub.2015.06.045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cub.2015.06.045</ArticleId><ArticleId IdType="pmc">PMC4546534</ArticleId><ArticleId IdType="pubmed">26234214</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu XL, Sun DD, Zheng MT, Li XT, Niu HH, Zhang L, Zhou ZW, et al. Maraviroc promotes recovery from traumatic brain injury in mice by suppression of neuroinflammation and activation of neurotoxic reactive astrocytes. Neural Regen Res. 2023;18(1):141&#x2013;149. doi: 10.4103/1673-5374.344829.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/1673-5374.344829</ArticleId><ArticleId IdType="pmc">PMC9241405</ArticleId><ArticleId IdType="pubmed">35799534</ArticleId></ArticleIdList></Reference><Reference><Citation>Medeiros GA, Silv&#xe9;rio JC, Marino AP, Roff&#xea; E, Vieira V, Kroll-Palhares K, Carvalho CE, Silva AA, et al. Treatment of chronically Trypanosoma cruzi-infected mice with a CCR1/CCR5 antagonist (Met-RANTES) results in amelioration of cardiac tissue damage. Microbes Infect. 2009;11(2):264&#x2013;273. doi: 10.1016/j.micinf.2008.11.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micinf.2008.11.012</ArticleId><ArticleId IdType="pubmed">19100857</ArticleId></ArticleIdList></Reference><Reference><Citation>Webber CJ, Murphy CN, Rond&#xf3;n-Ortiz AN, van der Spek SJF, Kelly EX, Lampl NM, Chiesa G, et al. Human herpesvirus 8 ORF57 protein is able to reduce TDP-43 pathology: network analysis identifies interacting pathways. Hum Mol Genet. 2023;32(20):2966&#x2013;2980. doi: 10.1093/hmg/ddad122.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddad122</ArticleId><ArticleId IdType="pmc">PMC10549787</ArticleId><ArticleId IdType="pubmed">37522762</ArticleId></ArticleIdList></Reference><Reference><Citation>Huntley ML, Gao J, Termsarasab P, Wang L, Zeng S, Thammongkolchai T, Liu Y, et al. Association between TDP-43 and mitochondria in inclusion body myositis. Lab Invest. 2019;99(7):1041&#x2013;1048. doi: 10.1038/s41374-019-0233-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41374-019-0233-x</ArticleId><ArticleId IdType="pmc">PMC6609472</ArticleId><ArticleId IdType="pubmed">30742062</ArticleId></ArticleIdList></Reference><Reference><Citation>Idrees D, Kumar V. SARS-CoV-2 spike protein interactions with amyloidogenic proteins: potential clues to neurodegeneration. Biochem Biophys Res Commun. 2021;554:94&#x2013;98. doi: 10.1016/j.bbrc.2021.03.100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2021.03.100</ArticleId><ArticleId IdType="pmc">PMC7988450</ArticleId><ArticleId IdType="pubmed">33789211</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang K, Wang C, Vagts C, Raguveer V, Finn PW, Perkins DL. Long non-coding RNAs (lncRNAs) NEAT1 and MALAT1 are differentially expressed in severe COVID-19 patients: an integrated single-cell analysis. PLoS ONE. 2022;17(1):e0261242. doi: 10.1371/journal.pone.0261242.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0261242</ArticleId><ArticleId IdType="pmc">PMC8746747</ArticleId><ArticleId IdType="pubmed">35007307</ArticleId></ArticleIdList></Reference><Reference><Citation>Menon MP, Hua KF. The long non-coding RNAs: paramount regulators of the NLRP3 inflammasome. Front Immunol. 2020;11:569524. doi: 10.3389/fimmu.2020.569524.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.569524</ArticleId><ArticleId IdType="pmc">PMC7546312</ArticleId><ArticleId IdType="pubmed">33101288</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamann PD, Roux BT, Heward JA, Love S, McHugh NJ, Jones SW, Lindsay MA. Transcriptional profiling identifies differential expression of long non-coding RNAs in Jo-1 associated and inclusion body myositis. Sci Rep. 2017;7(1):8024. doi: 10.1038/s41598-017-08603-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-08603-9</ArticleId><ArticleId IdType="pmc">PMC5556005</ArticleId><ArticleId IdType="pubmed">28808260</ArticleId></ArticleIdList></Reference><Reference><Citation>Askanas V, Engel WK, Nogalska A. Inclusion body myositis: a degenerative muscle disease associated with intra-muscle fiber multi-protein aggregates, proteasome inhibition, endoplasmic reticulum stress and decreased lysosomal degradation. Brain Pathol. 2009;19(3):493&#x2013;506. doi: 10.1111/j.1750-3639.2009.00290.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1750-3639.2009.00290.x</ArticleId><ArticleId IdType="pmc">PMC8094750</ArticleId><ArticleId IdType="pubmed">19563541</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghannam K, Martinez-Gamboa L, Spengler L, Krause S, Smiljanovic B, Bonin M, Bhattarai S, et al. Upregulation of immunoproteasome subunits in myositis indicates active inflammation with involvement of antigen presenting cells, CD8 T-cells and IFNGamma. PLoS ONE. 2014;9(8):e104048. doi: 10.1371/journal.pone.0104048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0104048</ArticleId><ArticleId IdType="pmc">PMC4123911</ArticleId><ArticleId IdType="pubmed">25098831</ArticleId></ArticleIdList></Reference><Reference><Citation>van den Eshof BL, Medfai L, Nolfi E, Wawrzyniuk M, Sijts AJAM. The function of immunoproteasomes&#x2014;an immunologists&#x2019; perspective. Cells. 2021;10(12):3360. doi: 10.3390/cells10123360.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10123360</ArticleId><ArticleId IdType="pmc">PMC8699091</ArticleId><ArticleId IdType="pubmed">34943869</ArticleId></ArticleIdList></Reference><Reference><Citation>Wellington D, Yin Z, Yu Z, Heilig R, Davis S, Fischer R, Felce SL, et al. SARS-CoV-2 mutations affect antigen processing by the proteasome to alter CD8+ T cell responses. Heliyon. 2023;9(10):e20076. doi: 10.1016/j.heliyon.2023.e20076.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.heliyon.2023.e20076</ArticleId><ArticleId IdType="pmc">PMC10570596</ArticleId><ArticleId IdType="pubmed">37842619</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrer I, Martin B, Castano JG, Lucas JJ, Moreno D, Olive M. Proteasomal expression, induction of immunoproteasome subunits, and local MHC class I presentation in myofibrillar myopathy and inclusion body myositis. J Neuropathol Exp Neurol. 2004;63(5):484&#x2013;498. doi: 10.1093/jnen/63.5.484.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnen/63.5.484</ArticleId><ArticleId IdType="pubmed">15198127</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolko L, Jiang W, Tawara N, Landon-Cardinal O, Anquetil C, Benveniste O, Allenbach Y. The role of interferons type I, II and III in myositis: a review. Brain Pathol. 2021;31(3):e12955. doi: 10.1111/bpa.12955.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bpa.12955</ArticleId><ArticleId IdType="pmc">PMC8412069</ArticleId><ArticleId IdType="pubmed">34043262</ArticleId></ArticleIdList></Reference><Reference><Citation>Ivanidze J, Hoffmann R, Lochmuller H, Engel AG, Hohlfeld R, Dornmair K. Inclusion body myositis: laser microdissection reveals differential up-regulation of IFN-gamma signaling cascade in attacked versus nonattacked myofibers. Am J Pathol. 2011;179(3):1347&#x2013;1359. doi: 10.1016/j.ajpath.2011.05.055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajpath.2011.05.055</ArticleId><ArticleId IdType="pmc">PMC3157228</ArticleId><ArticleId IdType="pubmed">21855683</ArticleId></ArticleIdList></Reference><Reference><Citation>Ekholm L, Vosslamber S, Tjarnlund A, de Jong TD, Betteridge Z, McHugh N, Plestilova L, et al. Autoantibody specificities and type I interferon pathway activation in idiopathic inflammatory myopathies. Scand J Immunol. 2016;84(2):100&#x2013;109. doi: 10.1111/sji.12449.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/sji.12449</ArticleId><ArticleId IdType="pubmed">27173897</ArticleId></ArticleIdList></Reference><Reference><Citation>Angeles A, Fung G, Luo H. Immune and non-immune functions of the immunoproteasome. Front Biosci (Landmark Ed) 2012;17(5):1904&#x2013;1916. doi: 10.1093/jnen/60.1.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnen/60.1.1</ArticleId><ArticleId IdType="pubmed">22201844</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayaki T, Murata K, Kanazawa N, Uruha A, Ohmura K, Sugie K, Kasagi S, et al. Myositis with sarcoplasmic inclusions in Nakajo-Nishimura syndrome: a genetic inflammatory myopathy. Neuropathol Appl Neurobiol. 2020;46(6):579&#x2013;587. doi: 10.1111/nan.12614.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nan.12614</ArticleId><ArticleId IdType="pubmed">32144790</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinal-Fernandez I, Casal-Dominguez M, Derfoul A, Pak K, Plotz P, Miller FW, Milisenda JC, et al. Identification of distinctive interferon gene signatures in different types of myositis. Neurology. 2019;93(12):e1193&#x2013;e1204. doi: 10.1212/WNL.0000000000008128.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000008128</ArticleId><ArticleId IdType="pmc">PMC6808530</ArticleId><ArticleId IdType="pubmed">31434690</ArticleId></ArticleIdList></Reference><Reference><Citation>Rigolet M, Hou C, Baba Amer Y, Aouizerate J, Periou B, Gherardi RK, et al. Distinct interferon signatures stratify inflammatory and dysimmune myopathies. RMD Open. 2019;5(1):e000811. doi: 10.1136/rmdopen-2018-000811.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/rmdopen-2018-000811</ArticleId><ArticleId IdType="pmc">PMC6397431</ArticleId><ArticleId IdType="pubmed">30886734</ArticleId></ArticleIdList></Reference><Reference><Citation>Goronzy JJ, Weyand CM. Mechanisms underlying T cell ageing. Nat Rev Immunol. 2019;19(9):573&#x2013;583. doi: 10.1038/s41577-019-0180-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-019-0180-1</ArticleId><ArticleId IdType="pmc">PMC7584388</ArticleId><ArticleId IdType="pubmed">31186548</ArticleId></ArticleIdList></Reference><Reference><Citation>Naddaf E, Shelly S, Mandrekar J, Chamberlain AM, Hoffman EM, Ernste FC, Liewluck T. Survival and associated comorbidities in inclusion body myositis. Rheumatology (Oxford) 2022;61(5):2016&#x2013;2024. doi: 10.1093/rheumatology/keab716.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keab716</ArticleId><ArticleId IdType="pmc">PMC9071572</ArticleId><ArticleId IdType="pubmed">34534271</ArticleId></ArticleIdList></Reference><Reference><Citation>Goyal NA, Coulis G, Duarte J, Farahat PK, Mannaa AH, Cauchii J, Irani T, et al. Immunophenotyping of inclusion body myositis blood T and NK cells. Neurology. 2022;98(13):e1374&#x2013;e1383. doi: 10.1212/WNL.0000000000200013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000200013</ArticleId><ArticleId IdType="pmc">PMC8967422</ArticleId><ArticleId IdType="pubmed">35131904</ArticleId></ArticleIdList></Reference><Reference><Citation>Eloranta ML, Barbasso Helmers S, Ulfgren AK, Ronnblom L, Alm GV, Lundberg IE. A possible mechanism for endogenous activation of the type I interferon system in myositis patients with anti-Jo-1 or anti-Ro 52/anti-Ro 60 autoantibodies. Arthritis Rheum. 2007;56(9):3112&#x2013;3124. doi: 10.1002/art.22860.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.22860</ArticleId><ArticleId IdType="pubmed">17763410</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones EL, Laidlaw SM, Dustin LB. TRIM21/Ro52&#x2014;roles in innate immunity and autoimmune disease. Front Immunol. 2021;12:738473. doi: 10.3389/fimmu.2021.738473.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.738473</ArticleId><ArticleId IdType="pmc">PMC8450407</ArticleId><ArticleId IdType="pubmed">34552597</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinal-Fernandez I, Casal-Dominguez M, Derfoul A, Pak K, Miller FW, Milisenda JC, Grau-Junyent JM. Machine learning algorithms reveal unique gene expression profiles in muscle biopsies from patients with different types of myositis. Ann Rheum Dis. 2020;79(9):1234&#x2013;1242. doi: 10.1136/annrheumdis-2019-216599.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2019-216599</ArticleId><ArticleId IdType="pmc">PMC10461844</ArticleId><ArticleId IdType="pubmed">32546599</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai Y, Zhu Y, Zheng J, Zhang Y, Chen W. NBR1 mediates autophagic degradation of IRF3 to negatively regulate type I interferon production. Biochem Biophys Res Commun. 2022;623:140&#x2013;147. doi: 10.1016/j.bbrc.2022.07.043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2022.07.043</ArticleId><ArticleId IdType="pubmed">35914352</ArticleId></ArticleIdList></Reference><Reference><Citation>D'Agostino C, Nogalska A, Cacciottolo M, Engel WK, Askanas V. Abnormalities of NBR1, a novel autophagy-associated protein, in muscle fibers of sporadic inclusion-body myositis. Acta Neuropathol. 2011;122(5):627&#x2013;636. doi: 10.1007/s00401-011-0874-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-011-0874-3</ArticleId><ArticleId IdType="pubmed">21935636</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamashita S, Matsuo Y, Tawara N, Hara K, Yamamoto M, Nishikami T, Kawakami K, et al. CYLD dysregulation in pathogenesis of sporadic inclusion body myositis. Sci Rep. 2019;9(1):11606. doi: 10.1038/s41598-019-48115-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-48115-2</ArticleId><ArticleId IdType="pmc">PMC6690995</ArticleId><ArticleId IdType="pubmed">31406156</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q, Jia Q, Gao W, Zhang W. The role of deubiquitinases in virus replication and host innate immune response. Front Microbiol. 2022;13:839624. doi: 10.3389/fmicb.2022.839624.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2022.839624</ArticleId><ArticleId IdType="pmc">PMC8908266</ArticleId><ArticleId IdType="pubmed">35283827</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasset-Rosa F, Lu S, Yu H, Chen C, Melamed Z, Guo L, Shorter J, et al. Cytoplasmic TDP-43 de-mixing independent of stress granules drives inhibition of nuclear import, loss of nuclear TDP-43, and cell death. Neuron. 2019;102(2):339&#x2013;357. doi: 10.1016/j.neuron.2019.02.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2019.02.038</ArticleId><ArticleId IdType="pmc">PMC6548321</ArticleId><ArticleId IdType="pubmed">30853299</ArticleId></ArticleIdList></Reference><Reference><Citation>Adler BL, Christopher-Stine L. Triggers of inflammatory myopathy: insights into pathogenesis. Discov Med. 2018;25(136):75&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5921929</ArticleId><ArticleId IdType="pubmed">29579414</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh H, Talapatra P, Arya S, Gupta V. Viral myositis as a close mimicker of polymyositis. Ann Trop Med Public Health. 2013;6:324&#x2013;326. doi: 10.4103/1755-6783.120997.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/1755-6783.120997</ArticleId></ArticleIdList></Reference><Reference><Citation>Manzano GS, Woods JK, Amato AA. Covid-19-associated myopathy caused by type I interferonopathy. N Engl J Med. 2020;383(24):2389&#x2013;2390. doi: 10.1056/NEJMc2031085.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2031085</ArticleId><ArticleId IdType="pmc">PMC7722689</ArticleId><ArticleId IdType="pubmed">33216474</ArticleId></ArticleIdList></Reference><Reference><Citation>Uruha A, Noguchi S, Hayashi YK, Tsuburaya RS, Yonekawa T, Nonaka I, Nishino I. Hepatitis C virus infection in inclusion body myositis: a case-control study. Neurology. 2016;86(3):211&#x2013;217. doi: 10.1212/WNL.0000000000002291.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000002291</ArticleId><ArticleId IdType="pubmed">26683644</ArticleId></ArticleIdList></Reference><Reference><Citation>Eura N. Anti-cytosolic 5'-nucleotidase 1A (cN1A) positivity in muscle is helpful in the diagnosis of sporadic inclusion body myositis: a study of 35 Japanese patients. J Neurol Neurosci. 2016 doi: 10.3390/biomedicines11071963.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines11071963</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuura E, Umehara F, Nose H, Higuchi I, Matsuoka E, Izumi K, Kubota R, et al. Inclusion body myositis associated with human T-lymphotropic virus-type I infection: eleven patients from an endemic area in Japan. J Neuropathol Exp Neurol. 2008;67(1):41&#x2013;49. doi: 10.1097/nen.0b013e31815f38b7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/nen.0b013e31815f38b7</ArticleId><ArticleId IdType="pubmed">18091562</ArticleId></ArticleIdList></Reference><Reference><Citation>Ou SH, Wu F, Harrich D, Garc&#xed;a-Mart&#xed;nez LF, Gaynor RB. Cloning and characterization of a novel cellular protein, TDP-43, that binds to human immunodeficiency virus type 1 TAR DNA sequence motifs. J Virol. 1995;69(6):3584&#x2013;3596. doi: 10.1128/JVI.69.6.3584-3596.1995.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.69.6.3584-3596.1995</ArticleId><ArticleId IdType="pmc">PMC189073</ArticleId><ArticleId IdType="pubmed">7745706</ArticleId></ArticleIdList></Reference><Reference><Citation>Nehls J, Koppensteiner H, Brack-Werner R, Floss T, Schindler M. HIV-1 replication in human immune cells is independent of TAR DNA binding protein 43 (TDP-43) expression. PLoS ONE. 2014;9(8):e105478. doi: 10.1371/journal.pone.0105478.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0105478</ArticleId><ArticleId IdType="pmc">PMC4134290</ArticleId><ArticleId IdType="pubmed">25127017</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou L, Miranda-Saksena M, Saksena NK. Viruses and neurodegeneration. Virol J. 2013;10:172. doi: 10.1186/1743-422X-10-172.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-10-172</ArticleId><ArticleId IdType="pmc">PMC3679988</ArticleId><ArticleId IdType="pubmed">23724961</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalal F, Dalal H, McNew G. COVID-19-induced sporadic inclusion body myositis. Cureus. 2022;14(10):e30808. doi: 10.7759/cureus.30808.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.30808</ArticleId><ArticleId IdType="pmc">PMC9701533</ArticleId><ArticleId IdType="pubmed">36447724</ArticleId></ArticleIdList></Reference><Reference><Citation>Saud A, Naveen R, Aggarwal R, Gupta L. COVID-19 and myositis: what we know so far. Curr Rheumatol Rep. 2021;23(8):63. doi: 10.1007/s11926-021-01023-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11926-021-01023-9</ArticleId><ArticleId IdType="pmc">PMC8254439</ArticleId><ArticleId IdType="pubmed">34216297</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacob S, Kapadia R, Soule T, Luo H, Schellenberg KL, Douville RN, Pfeffer G. Neuromuscular complications of SARS-CoV-2 and other viral infections. Front Neurol. 2022;13:914411. doi: 10.3389/fneur.2022.914411.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2022.914411</ArticleId><ArticleId IdType="pmc">PMC9263266</ArticleId><ArticleId IdType="pubmed">35812094</ArticleId></ArticleIdList></Reference><Reference><Citation>Swartzman I, Gu JJ, Toner Z, Grover R, Suresh L, Ullman LE. Prevalence of myositis-specific autoantibodies and myositis-associated autoantibodies in COVID-19 patients: a pilot study and literature review. Cureus. 2022;14(9):e29752. doi: 10.7759/cureus.29752.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.29752</ArticleId><ArticleId IdType="pmc">PMC9617586</ArticleId><ArticleId IdType="pubmed">36324355</ArticleId></ArticleIdList></Reference><Reference><Citation>Holzer MT, Krusche M, Ruffer N, Haberstock H, Stephan M, Huber TB, Kotter I. New-onset dermatomyositis following SARS-CoV-2 infection and vaccination: a case-based review. Rheumatol Int. 2022;42(12):2267&#x2013;2276. doi: 10.1007/s00296-022-05176-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-022-05176-3</ArticleId><ArticleId IdType="pmc">PMC9358381</ArticleId><ArticleId IdType="pubmed">35939078</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, Kang L, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397(10270):220&#x2013;232. doi: 10.1016/S0140-6736(20)32656-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32656-8</ArticleId><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, Yuan D, Chen DG, Ng RH, Wang K, Choi J, Li S, et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. 2022;185(5):881&#x2013;895. doi: 10.1016/j.cell.2022.01.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.01.014</ArticleId><ArticleId IdType="pmc">PMC8786632</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramakrishnan RK, Kashour T, Hamid Q, Halwani R, Tleyjeh IM. Unraveling the mystery surrounding post-acute sequelae of COVID-19. Front Immunol. 2021;12:686029. doi: 10.3389/fimmu.2021.686029.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.686029</ArticleId><ArticleId IdType="pmc">PMC8278217</ArticleId><ArticleId IdType="pubmed">34276671</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang R, Roy B, Wu Q, Mohanty S, Nowak RJ, Shaw AC, Kleinstein SH, O'Connor KC. The plasma cell infiltrate populating the muscle tissue of patients with inclusion body myositis features distinct B cell receptor repertoire properties. Immunohorizons. 2023;7(5):310&#x2013;322. doi: 10.4049/immunohorizons.2200078.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/immunohorizons.2200078</ArticleId><ArticleId IdType="pmc">PMC10579972</ArticleId><ArticleId IdType="pubmed">37171806</ArticleId></ArticleIdList></Reference><Reference><Citation>McLeish E, Sooda A, Slater N, Kachigunda B, Beer K, Paramalingam S, Lamont PJ, Chopra A, Mastaglia FL, Needham M, Coudert JD. Uncovering the significance of expanded CD8+ large granular lymphocytes in inclusion body myositis: Insights into T cell phenotype and functional alterations, and disease severity. Front Immunol. 2023;14:1153789. doi: 10.3389/fimmu.2023.1153789.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1153789</ArticleId><ArticleId IdType="pmc">PMC10098158</ArticleId><ArticleId IdType="pubmed">37063893</ArticleId></ArticleIdList></Reference><Reference><Citation>Rose A, Isenalumhe L, Van den Bergh M, Sokol L. Clonal T-cell large granular lymphocytic disorders manifesting in patients with HIV-1 infection: case series and review of the literature. Mediterr J Hematol Infect Dis. 2018;10(1):e2018036. doi: 10.4084/MJHID.2018.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.4084/MJHID.2018.036</ArticleId><ArticleId IdType="pmc">PMC6039084</ArticleId><ArticleId IdType="pubmed">30002792</ArticleId></ArticleIdList></Reference><Reference><Citation>Goronzy JJ, Li G, Yang Z, Weyand CM. The Janus head of T cell aging&#x2014;autoimmunity and immunodeficiency. Front Immunol. 2013;4:131. doi: 10.3389/fimmu.2013.00131.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2013.00131</ArticleId><ArticleId IdType="pmc">PMC3671290</ArticleId><ArticleId IdType="pubmed">23761790</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothwell S, Cooper RG, Lundberg IE, Gregersen PK, Hanna MG, Machado PM, Herbert MK, et al. Immune-array analysis in sporadic inclusion body myositis reveals HLA-DRB1 amino acid heterogeneity across the myositis spectrum. Arthritis Rheumatol. 2017;69(5):1090&#x2013;1099. doi: 10.1002/art.40045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.40045</ArticleId><ArticleId IdType="pmc">PMC5516174</ArticleId><ArticleId IdType="pubmed">28086002</ArticleId></ArticleIdList></Reference><Reference><Citation>Rojana-Udomsart A, Bundell C, James I, Castley A, Martinez P, Christiansen F, Hollingsworth P, Mastaglia F. Frequency of autoantibodies and correlation with HLA-DRB1 genotype in sporadic inclusion body myositis (s-IBM): a population control study. J Neuroimmunol. 2012;249(1&#x2013;2):66&#x2013;70. doi: 10.1016/j.jneuroim.2012.04.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2012.04.007</ArticleId><ArticleId IdType="pubmed">22554526</ArticleId></ArticleIdList></Reference><Reference><Citation>Slater N, Sooda A, McLeish E, Beer K, Brusch A, Shakya R, Bundell C, James I, Chopra A, Mastaglia FL, Needham M, Coudert JD. High-resolution HLA genotyping in inclusion body myositis refines 8.1 ancestral haplotype association to DRB1*03:01:01 and highlights pathogenic role of arginine-74 of DR&#x3b2;1 chain. J Autoimmun. 2024;142:103150. doi: 10.1016/j.jaut.2023.103150.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2023.103150</ArticleId><ArticleId IdType="pubmed">38043487</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller FW, Lamb JA, Schmidt J, Nagaraju K. Risk factors and disease mechanisms in myositis. Nat Rev Rheumatol. 2018;14(5):255&#x2013;268. doi: 10.1038/nrrheum.2018.48.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrrheum.2018.48</ArticleId><ArticleId IdType="pmc">PMC6745704</ArticleId><ArticleId IdType="pubmed">29674613</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranasinghe S, Cutler S, Davis I, Lu R, Soghoian DZ, Qi Y, Sidney J, Kranias G, Flanders MD, Lindqvist M, Kuhl B, Alter G, Deeks SG, Walker BD, Gao X, Sette A, Carrington M, Streeck H. Association of HLA-DRB1-restricted CD4+ T cell responses with HIV immune control. Nat Med. 2013;19(7):930&#x2013;933. doi: 10.1038/nm.3229.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.3229</ArticleId><ArticleId IdType="pmc">PMC3974408</ArticleId><ArticleId IdType="pubmed">23793098</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrett S, Ryan E, Crowe J. Association of the HLA-DRB1*01 allele with spontaneous viral clearance in an Irish cohort infected with hepatitis C virus via contaminated anti-D immunoglobulin. J Hepatol. 1999;30(6):979&#x2013;983. doi: 10.1016/s0168-8278(99)80249-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0168-8278(99)80249-9</ArticleId><ArticleId IdType="pubmed">10406173</ArticleId></ArticleIdList></Reference><Reference><Citation>Bettencourt A, Carvalho C, Leal B, Br&#xe1;s S, Lopes D, Martins da Silva A, Santos E, et al. The protective role of HLA-DRB1(&#x2217;)13 in autoimmune diseases. J Immunol Res. 2015 doi: 10.1155/2015/948723.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2015/948723</ArticleId><ArticleId IdType="pmc">PMC4641944</ArticleId><ArticleId IdType="pubmed">26605347</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferre AL, Hunt PW, McConnell DH, Morris MM, Garcia JC, Pollard RB, Yee HF, et al. HIV controllers with HLA-DRB1*13 and HLA-DQB1*06 alleles have strong, polyfunctional mucosal CD4+ T-cell responses. J Virol. 2010;84(21):11020&#x2013;11029. doi: 10.1128/JVI.00980-10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00980-10</ArticleId><ArticleId IdType="pmc">PMC2953185</ArticleId><ArticleId IdType="pubmed">20719952</ArticleId></ArticleIdList></Reference><Reference><Citation>Kummee P, Tangkijvanich P, Poovorawan Y, Hirankarn N. Association of HLA-DRB1*13 and TNF-alpha gene polymorphisms with clearance of chronic hepatitis B infection and risk of hepatocellular carcinoma in Thai population. J Viral Hepat. 2007;14(12):841&#x2013;848. doi: 10.1111/j.1365-2893.2007.00880.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2893.2007.00880.x</ArticleId><ArticleId IdType="pubmed">18070287</ArticleId></ArticleIdList></Reference><Reference><Citation>James LM, Christova P, Lewis SM, Engdahl BE, Georgopoulos A, Georgopoulos AP. Protective effect of human leukocyte antigen (HLA) allele DRB1*13:02 on age-related brain gray matter volume reduction in healthy women. EBioMedicine. 2018;29:31&#x2013;37. doi: 10.1016/j.ebiom.2018.02.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2018.02.005</ArticleId><ArticleId IdType="pmc">PMC5925575</ArticleId><ArticleId IdType="pubmed">29452862</ArticleId></ArticleIdList></Reference><Reference><Citation>Chikata T, Paes W, Kuse N, Partridge T, Gatanaga H, Zhang Y, Kuroki K, Maenaka K, Ternette N, Oka S, Borrow P, Takiguchi M. Impact of micropolymorphism outside the peptide binding groove in the clinically relevant allele HLA-C*14 on T cell responses in HIV-1 infection. J Virol. 2022;96(10):e0043222. doi: 10.1128/jvi.00432-22.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.00432-22</ArticleId><ArticleId IdType="pmc">PMC9131871</ArticleId><ArticleId IdType="pubmed">35475667</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng L, Chen K, Xiao F, Zhu CY, Bai JY, Tan S, Long L, et al. Potential common molecular mechanisms between Sj&#xf6;gren syndrome and inclusion body myositis: a bioinformatic analysis and in vivo validation. Front Immunol. 2023;14:1161476. doi: 10.3389/fimmu.2023.1161476.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1161476</ArticleId><ArticleId IdType="pmc">PMC10160489</ArticleId><ArticleId IdType="pubmed">37153570</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin A, Yan WH. The emerging roles of human leukocyte antigen-F in immune modulation and viral infection. Front Immunol. 2019;10:964. doi: 10.3389/fimmu.2019.00964.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.00964</ArticleId><ArticleId IdType="pmc">PMC6524545</ArticleId><ArticleId IdType="pubmed">31134067</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, Khasanova E, Zhang L. Bioinformatics analysis of gene expression profiles of Inclusion body myositis. Scand J Immunol. 2020;91(6):e12887. doi: 10.1111/sji.12887.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/sji.12887</ArticleId><ArticleId IdType="pubmed">32259312</ArticleId></ArticleIdList></Reference><Reference><Citation>Jasinska AJ, Pandrea I, Apetrei C. CCR5 as a coreceptor for human immunodeficiency virus and simian immunodeficiency viruses: a prototypic love-hate affair. Front Immunol. 2022;13:835994. doi: 10.3389/fimmu.2022.835994.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.835994</ArticleId><ArticleId IdType="pmc">PMC8829453</ArticleId><ArticleId IdType="pubmed">35154162</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellwanger JH, Kulmann-Leal B, Kaminski VL, Rodrigues AG, Bragatte MAS, Chies JAB. Beyond HIV infection: neglected and varied impacts of CCR5 and CCR5&#x394;32 on viral diseases. Virus Res. 2020;286:198040. doi: 10.1016/j.virusres.2020.198040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2020.198040</ArticleId><ArticleId IdType="pmc">PMC7260533</ArticleId><ArticleId IdType="pubmed">32479976</ArticleId></ArticleIdList></Reference><Reference><Citation>Roos A, Preusse C, Hathazi D, Goebel HH, Stenzel W. Proteomic profiling unravels a key role of specific macrophage subtypes in sporadic inclusion body myositis. Front Immunol. 2019;10:1040. doi: 10.3389/fimmu.2019.01040.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.01040</ArticleId><ArticleId IdType="pmc">PMC6522546</ArticleId><ArticleId IdType="pubmed">31143183</ArticleId></ArticleIdList></Reference><Reference><Citation>Trifone C, Salido J, Ruiz MJ, Leng L, Quiroga MF, Salom&#xf3;n H, Bucala R, et al. Interaction between macrophage migration inhibitory factor and CD74 in human immunodeficiency virus type I infected primary monocyte-derived macrophages triggers the production of proinflammatory mediators and enhances infection of unactivated CD4+&#xa0;T cells. Front Immunol. 2018;9:1494. doi: 10.3389/fimmu.2018.01494.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.01494</ArticleId><ArticleId IdType="pmc">PMC6030361</ArticleId><ArticleId IdType="pubmed">29997630</ArticleId></ArticleIdList></Reference><Reference><Citation>Connolly CM, Plomp L, Paik JJ, Allenbach Y. Possible future avenues for myositis therapeutics: DM, IMNM and IBM. Best Pract Res Clin Rheumatol. 2022;36(2):101762. doi: 10.1016/j.berh.2022.101762.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.berh.2022.101762</ArticleId><ArticleId IdType="pubmed">35778272</ArticleId></ArticleIdList></Reference><Reference><Citation>Astorga-Gamaza A, Perea D, Sanchez-Gaona N, Calvet-Mirabent M, Gallego-Cort&#xe9;s A, Grau-Exp&#xf3;sito J, Sanchez-Cerrillo I, Rey J, Castellv&#xed; J, Curran A, Burgos J, Navarro J, Suanzes P, Falc&#xf3; V, Genesc&#xe0; M, Mart&#xed;n-Gayo E, Buzon MJ. KLRG1 expression on natural killer cells is associated with HIV persistence, and its targeting promotes the reduction of the viral reservoir. Cell Rep Med. 2023;4(10):101202. doi: 10.1016/j.xcrm.2023.101202.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2023.101202</ArticleId><ArticleId IdType="pmc">PMC10591043</ArticleId><ArticleId IdType="pubmed">37741278</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu CH, Davidson S, Harapas CR, Hilton JB, Mlodzianoski MJ, Laohamonthonkul P, Louis C, et al. TDP-43 triggers mitochondrial DNA release via mPTP to activate cGAS/STING in ALS. Cell. 2020;183(3):636&#x2013;649. doi: 10.1016/j.cell.2020.09.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.09.020</ArticleId><ArticleId IdType="pmc">PMC7599077</ArticleId><ArticleId IdType="pubmed">33031745</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori F, Tada M, Kon T, Miki Y, Tanji K, Kurotaki H, Tomiyama M, et al. Phosphorylated TDP-43 aggregates in skeletal and cardiac muscle are a marker of myogenic degeneration in amyotrophic lateral sclerosis and various conditions. Acta Neuropathol Commun. 2019;7(1):165. doi: 10.1186/s40478-019-0824-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-019-0824-1</ArticleId><ArticleId IdType="pmc">PMC6816170</ArticleId><ArticleId IdType="pubmed">31661037</ArticleId></ArticleIdList></Reference><Reference><Citation>Damian L, Login CC, Solomon C, Belizna C, Encica S, Urian L, Jurcut C, et al. Inclusion body myositis and neoplasia: a narrative review. Int J Mol Sci. 2022;23(13):7358. doi: 10.3390/ijms23137358.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23137358</ArticleId><ArticleId IdType="pmc">PMC9266341</ArticleId><ArticleId IdType="pubmed">35806366</ArticleId></ArticleIdList></Reference><Reference><Citation>Pozzi S, Codron P, Soucy G, Renaud L, Cordeau PJ, Dutta K, Bareil C, Julien JP. Monoclonal full-length antibody against TAR DNA binding protein 43 reduces related proteinopathy in neurons. JCI Insight. 2020;5(21):e140420. doi: 10.1172/jci.insight.140420.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.140420</ArticleId><ArticleId IdType="pmc">PMC7710295</ArticleId><ArticleId IdType="pubmed">33021970</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang P, Deng J, Dong J, Liu J, Bigio EH, Mesulam M, Wang T, et al. TDP-43 induces mitochondrial damage and activates the mitochondrial unfolded protein response. PLoS Genet. 2019;15(5):e1007947. doi: 10.1371/journal.pgen.1007947.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1007947</ArticleId><ArticleId IdType="pmc">PMC6524796</ArticleId><ArticleId IdType="pubmed">31100073</ArticleId></ArticleIdList></Reference><Reference><Citation>Njomen E, Tepe JJ. Proteasome activation as a new therapeutic approach to target proteotoxic disorders. J Med Chem. 2019;62(14):6469&#x2013;6481. doi: 10.1021/acs.jmedchem.9b00101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.9b00101</ArticleId><ArticleId IdType="pmc">PMC6745699</ArticleId><ArticleId IdType="pubmed">30839208</ArticleId></ArticleIdList></Reference><Reference><Citation>Moghadam-Kia S, Oddis CV. Current and new targets for treating myositis. Curr Opin Pharmacol. 2022;65:102257. doi: 10.1016/j.coph.2022.102257.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coph.2022.102257</ArticleId><ArticleId IdType="pubmed">35724455</ArticleId></ArticleIdList></Reference><Reference><Citation>Guglielmi V, Cheli M, Tonin P, Vattemi G. Sporadic inclusion body myositis at the crossroads between muscle degeneration, inflammation, and aging. Int J Mol Sci. 2024;25(5):2742. doi: 10.3390/ijms25052742.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms25052742</ArticleId><ArticleId IdType="pmc">PMC10932328</ArticleId><ArticleId IdType="pubmed">38473988</ArticleId></ArticleIdList></Reference><Reference><Citation>Terracciano C, Nogalska A, Engel WK, Askanas V. In AbetaPP-overexpressing cultured human muscle fibers proteasome inhibition enhances phosphorylation of AbetaPP751 and GSK3beta activation: effects mitigated by lithium and apparently relevant to sporadic inclusion-body myositis. J Neurochem. 2010;112(2):389&#x2013;396. doi: 10.1111/j.1471-4159.2009.06461.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2009.06461.x</ArticleId><ArticleId IdType="pmc">PMC2809129</ArticleId><ArticleId IdType="pubmed">19878439</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong N, Park JS, Kim HJ. Synapto-protective effect of lithium on HIV-1 Tat-induced synapse loss in rat hippocampal cultures. Anim Cells Syst (Seoul) 2021;26(1):1&#x2013;9. doi: 10.1080/19768354.2021.2018044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/19768354.2021.2018044</ArticleId><ArticleId IdType="pmc">PMC8928815</ArticleId><ArticleId IdType="pubmed">35308128</ArticleId></ArticleIdList></Reference><Reference><Citation>Schifitto G, Zhong J, Gill D, Peterson DR, Gaugh MD, Zhu T, Tivarus M, Cruttenden K, Maggirwar SB, Gendelman HE, Dewhurst S, Gelbard HA. Lithium therapy for human immunodeficiency virus type 1-associated neurocognitive impairment. J Neurovirol. 2009;15(2):176&#x2013;186. doi: 10.1080/13550280902758973.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13550280902758973</ArticleId><ArticleId IdType="pmc">PMC2747099</ArticleId><ArticleId IdType="pubmed">19306230</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>